High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy

Lucillia Bezu; Guido Kroemer

doi:10.1080/2162402X.2024.2432059

High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy

Lucillia Bezu, Guido Kroemer

Résultats de recherche: Contribution à un journal › !!Comment/debate

Résumé

Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.

langue originale	Anglais
Numéro d'article	2432059
journal	OncoImmunology
Volume	13
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2024.2432059
état	Publié - 1 janv. 2024

Accès au document

10.1080/2162402X.2024.2432059

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{c419f54f2bfb4ee8b3a07d22cb2d5d10,

title = "High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy",

abstract = "Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.",

keywords = "Biomarker, PD-1 blockade, cancer, chemotherapy, immunotherapy",

author = "Lucillia Bezu and Guido Kroemer",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

month = jan,

day = "1",

doi = "10.1080/2162402X.2024.2432059",

language = "English",

volume = "13",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - High circulating HMGB1 indicates good prognosis in patients with advanced leiomyosarcoma under chemoimmunotherapy

AU - Bezu, Lucillia

AU - Kroemer, Guido

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.

AB - Few clinical studies investigated the putative link between the activation of immunogenic cell death (ICD) and the oncological outcome. Recent data, published in a Phase 1b trial, demonstrated that an ICD-associated surge in the plasma concentration of high-mobility group box 1 (HMGB1) indicates favorable prognosis in patients with advanced leiomyosarcomas treated with the combination of doxorubicin, dacarbazine and nivolumab.

KW - Biomarker

KW - PD-1 blockade

KW - cancer

KW - chemotherapy

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85210070122&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2024.2432059

DO - 10.1080/2162402X.2024.2432059

M3 - Comment/debate

AN - SCOPUS:85210070122

SN - 2162-4011

VL - 13

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2432059

ER -